COVID-19疫情期间急性心肌梗死的管理:SCAI、ACC与ACEP共识声明
该共识由SCAI、ACC与ACEP联合制定,针对COVID-19疫情期间急性心肌梗死(AMI)的管理提出系统建议。文件指出COVID-19心血管表现复杂,可表现为AMI、模拟STEMI的心肌炎、应激性心肌病、非缺血性心肌病、冠脉痉挛或非特异性心肌损伤,且美国人群COVID-19患病率未知、存在无症状传播风险。建议聚焦于不同临床表现、医护人员个人防护装备(PPE)、急诊科与急救系统及心导管室(CCL)的角色以及区域STEMI救治体系。在PCI capable医院,直接PCI仍是STEMI的标准治疗,前提是能及时实施并由穿戴PPE的专家团队在专用CCL房间完成;在非PCI capable转诊医院或直接PCI无法执行或不被视为最佳选择的特定情况下,可考虑基于溶栓的策略。
要点
- 在PCI capable医院,直接PCI仍是COVID-19疫情期间STEMI患者的标准治疗,条件是由穿戴PPE的专家团队在专用CCL房间及时实施。
- 在非PCI capable转诊医院,或直接PCI无法执行或不被视为最佳选择的特定情况下,可考虑基于溶栓的策略。
- COVID-19患者可表现为AMI、模拟STEMI的心肌炎、应激性心肌病、非缺血性心肌病、冠脉痉挛或非特异性心肌损伤,需鉴别。
- 美国人群COVID-19患病率未知且存在无症状传播风险,为AMI救治决策带来挑战。
- 共识建议涵盖急诊科、急救系统、心导管室及区域STEMI救治体系的系统化协调。
适用人群与场景
- 需要心血管护理的缺血性心脏病患者,多数可能未感染新型冠状病毒。
- COVID-19疫情期间的急性心肌梗死(AMI)患者,包括STEMI及表现为模拟STEMI的心肌炎、应激性心肌病、非缺血性心肌病、冠脉痉挛或非特异性心肌损伤者。
处置流程与药物剂量
- 在PCI capable医院,直接PCI仍是STEMI患者的标准治疗,需能及时实施,由穿戴PPE的专家团队在专用CCL房间完成。
- 在非PCI capable转诊医院,或直接PCI无法执行或不被视为最佳选择的特定情况下,可考虑基于溶栓的策略。
- 根据患者不同临床表现进行系统评估与分类管理。
- 为医护人员配备适当的个人防护装备(PPE)。
- 明确急诊科、急救医疗系统及心导管室(CCL)在AMI救治中的角色。
- 协调区域STEMI救治体系。
研究设计与关键结果
- 该文件为SCAI、ACC与ACEP联合发布的共识声明,旨在为COVID-19疫情期间AMI患者的系统化救治提供建议。
- 文件识别出提供AMI救治建议的两大挑战:COVID-19心血管表现复杂(包括AMI、模拟STEMI的心肌炎、应激性心肌病、非缺血性心肌病、冠脉痉挛或非特异性心肌损伤);美国人群COVID-19患病率未知且存在无症状传播风险。
证据类型、等级与局限
- 证据类型:共识声明(指南/共识)。
- 制定机构:心血管造影与介入学会(SCAI)、美国心脏病学会(ACC)、美国急诊医师学会(ACEP)。
对床旁实践的改变
- 在PCI capable医院,对STEMI患者仍应优先考虑直接PCI,但须确保能及时实施、团队穿戴PPE并使用专用CCL房间。
- 在非PCI capable转诊医院或直接PCI无法执行/不被视为最佳选择的特定情况下,可考虑溶栓策略。
- 对表现为AMI的COVID-19患者,需考虑模拟STEMI的心肌炎、应激性心肌病、非缺血性心肌病、冠脉痉挛或非特异性心肌损伤等复杂表现。
- 救治流程需整合急诊科、急救医疗系统、心导管室及区域STEMI救治体系,并落实医护人员PPE。
指南或共识出处
- Management of acute myocardial infarction during the COVID-19 pandemic: A Consensus Statement from the Society for Cardiovascular Angiography and Interventions (SCAI), the American College of Cardiology (ACC), and the American College of Emergency Physicians (ACEP).
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
The worldwide pandemic caused by the novel acute respiratory syndrome coronavirus 2 has resulted in a new and lethal disease termed coronavirus disease 2019 (COVID-19). Although there is an association between cardiovascular disease and COVID-19, the majority of patients who need cardiovascular care for the management of ischemic heart disease may not be infected with this novel coronavirus. The objective of this document is to provide recommendations for a systematic approach for the care of patients with an acute myocardial infarction (AMI) during the COVID-19 pandemic. There is a recognition of two major challenges in providing recommendations for AMI care in the COVID-19 era. Cardiovascular manifestations of COVID-19 are complex with patients presenting with AMI, myocarditis simulating an ST-elevation myocardial infarction (STEMI) presentation, stress cardiomyopathy, non-ischemic cardiomyopathy, coronary spasm, or nonspecific myocardial injury, and the prevalence of COVID-19 disease in the US population remains unknown with risk of asymptomatic spread. This document addresses the care of these patients focusing on (a) varied clinical presentations; (b) appropriate personal protection equipment (PPE) for health care workers; (c) the roles of the emergency department, emergency medical system, and the cardiac catheterization laboratory (CCL); and (4) regional STEMI systems of care. During the COVID-19 pandemic, primary percutaneous coronary intervention (PCI) remains the standard of care for STEMI patients at PCI-capable hospitals when it can be provided in a timely manner, with an expert team outfitted with PPE in a dedicated CCL room. A fibrinolysis-based strategy may be entertained at non-PCI-capable referral hospitals or in specific situations where primary PCI cannot be executed or is not deemed the best option.
参考来源
- Mahmud E, Dauerman HL, Welt FGP, et al. Management of acute myocardial infarction during the COVID-19 pandemic: A Consensus Statement from the Society for Cardiovascular Angiography and Interventions (SCAI), the American College of Cardiology (ACC), and the American College of Emergency Physicians (ACEP). Catheter Cardiovasc Interv. 2020. PMID: 32311816. doi:10.1002/ccd.28946
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。